These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9831373)
1. Cancer treatment in Sweden--costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs. Ragnarson Tennvall G; Karlsson G Acta Oncol; 1998; 37(5):447-53. PubMed ID: 9831373 [TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068 [TBL] [Abstract][Full Text] [Related]
3. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors. Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712 [TBL] [Abstract][Full Text] [Related]
4. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299 [TBL] [Abstract][Full Text] [Related]
5. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy. Peroutka JA; Mutnick AH Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731 [TBL] [Abstract][Full Text] [Related]
6. The economic impact of the transition from branded to generic oncology drugs. Cheung WY; Kornelsen EA; Mittmann N; Leighl NB; Cheung M; Chan KK; Bradbury PA; Ng RCH; Chen BE; Ding K; Pater JL; Tu D; Hay AE Curr Oncol; 2019 Apr; 26(2):89-93. PubMed ID: 31043808 [TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. McBride A; Bonafede M; Cai Q; Princic N; Tran O; Pelletier C; Parisi M; Patel M Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1153-1160. PubMed ID: 28795609 [TBL] [Abstract][Full Text] [Related]
8. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Liu Z; Doan QV; Malin J; Leonard R Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473 [TBL] [Abstract][Full Text] [Related]
9. [Analysis of antineoplastic drugs used in Cancer Center, Sun Yat-sen University, during the period of 1996-2005]. Zhong JT; Huang HB; Lin ZC; Liu T; Lin PL Ai Zheng; 2006 Aug; 25(8):1052-8. PubMed ID: 16965693 [TBL] [Abstract][Full Text] [Related]
10. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Eldar-Lissai A; Cosler LE; Culakova E; Lyman GH Value Health; 2008; 11(2):172-9. PubMed ID: 18380630 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861 [TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer - cost for overtreatment with gemcitabine. Ansari D; Tingstedt B; Andersson R Acta Oncol; 2013 Aug; 52(6):1146-51. PubMed ID: 23244671 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. Guan H; Liu G; Xie F; Sheng Y; Shi L Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial. Maniadakis N; Dafni U; Fragoulakis V; Grimani I; Galani E; Fragkoulidi A; Fountzilas G Ann Oncol; 2009 Feb; 20(2):278-85. PubMed ID: 18842612 [TBL] [Abstract][Full Text] [Related]
15. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany]. Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162 [TBL] [Abstract][Full Text] [Related]
16. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Edwards SJ; Barton S; Thurgar E; Trevor N Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481 [TBL] [Abstract][Full Text] [Related]
17. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. Lyman GH Eur J Cancer; 2000 Apr; 36 Suppl 1():S15-21. PubMed ID: 10785605 [TBL] [Abstract][Full Text] [Related]
18. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer. Chisaki Y; Nakamura N; Yano Y Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952 [TBL] [Abstract][Full Text] [Related]
19. Evaluating new treatments for advanced cancer. Botwood N Br J Cancer; 2001 Jul; 85(1):139-40. PubMed ID: 11437417 [No Abstract] [Full Text] [Related]
20. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model. Rui M; Shi F; Shang Y; Meng R; Li H Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]